Skip to main content
BCRX logo

BCRX

BioCryst Pharmaceuticals, Inc.

$7.23

1.19%

Trade Ideas Performance

Latest Closed Trade Idea

$7.23

1.19%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

11

Social

9

About

Events of BioCryst Pharmaceuticals, Inc. (BCRX)

In the past six months, BioCryst Pharmaceuticals experienced several stock-impacting events: on November 4, 2026, the company reported stronger-than-expected Q3 2026 financial results, with total revenue of $180.3 million and diluted EPS of $0.14, leading to a 1.7% rise in BCRX shares, and raised its full-year 2026 total revenue guidance. BioCryst is also scheduled to present at investor conferences in November and December 2026. On August 25, 2026, ORLADEYO received approval for pediatric HAE patients in Japan. The company reported Q2 2026 earnings per share of $0.300 on August 5, 2026. In January 2026, BioCryst acquired Astria Therapeutics, Inc. for US$700 million, adding navenibart, a long-acting injectable HAE candidate, to its pipeline, with top-line data expected in Q3 2027. On December 12, 2025, the FDA approved the oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in pediatric patients aged 2 to less than 12 years.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)